Use of in vitro models to study the emergence of resistance Professor Inga Odenholt Department of Infectious Diseases University hospital, Malmö Sweden.

Slides:



Advertisements
Similar presentations
TREATMENT FOR SUPERIMPOSED PSEUDOMONAS AERUGINOSA INFECTION.
Advertisements

A 23 Variability in the Size of the Fluoroquinolone AUC/MIC for Antibacterial Effect in S.aureus: Impact for Clinical Breakpoints A. R. Noel, K.E. Bowker,
Quinolones: mechanisms of resistance
Animal Model PK/PD: A Tool for Drug Development
Prevention of Emergence of Resistance: A Pharmacodynamic Solution G.L. Drusano, M.D. Professor and Director Division of Clinical Pharmacology Clinical.
Improvement in Dose Selection Through Clinical Applications of PK/PD in Antimicrobial Drug Development Hartmut Derendorf, Ph.D. University of Florida.
Eccmid 2003 Aminoglycosiden bij neonaten Canisius-Wilhelmina Hospital Nijmegen, The Netherlands Johan W Mouton Relationship between bacterial killing,
Plasmids Chromosome Plasmid Plasmid + Transposon Plasmid + integron Plasmid+transposon +intergron Chromosome Chromosome + transposon Chromosome + transposon.
The Relationship between Daptomycin (DAP) Free drug AUC/MIC, Antibacterial effect (ABE) and Emergence of Resistance (EoR) in S.aureus. KE Bowker, AR Noel,
Overview of Use of PK-PD in Streamlining Drug Development William A. Craig Professor of Medicine University of Wisconsin.
Antibiotics Biotechnology II. Univ S. Carolina Antibiotics Disrupt Cell Wall Synthesis, Protein Synthesis, Nucleic Acid Synthesis and Metabolism.
Chapter 10: Restricting antibiotic use and optimizing dosing.
Pharmacodynamics of Glycopeptides Niels Frimodt-Møller, MD DMSc Dept. Of Microbiological R & D Statens Serum Institut, Copenhagen, Denmark.
Prevention of Emergence of Resistance: A Pharmacodynamic Solution G.L. Drusano, M.D. Professor and Director Division of Clinical Pharmacology Clinical.
Sub-MIC effects in vitro and in vivo Inga Odenholt, MD., Ph.D. Department of Infectious Diseases University hospital Malmö Sweden.
PK/PD of Antibiotics in relation to resistance Otto Cars MD Department of Medical Sciences Infectious diseases Uppsala University Sweden.
Synergism : what does it mean? JW Mouton Dept Medical Microbiology Canisius Wilhelmina Hospital Nijmegen, The Netherlands.
Rational Dosing: The Use of Plasma Concentrations vs. Tissue Concentrations Hartmut Derendorf, PhD University of Florida.
Application of PK/PD modeling for optimization of linezolid therapy Julia Zayezdnaya Zack.
8th ISAP Symposium Can PK/PD be used in everyday clinical practice? Francesco Scaglione Department of Pharmacology, Toxicology and Chemotherapy, University.
Pharmacodynamics of Antimicrobials in Animal Models William A. Craig, M.D. University of Wisconsin-Madison.
FADDI RAJESH V. DUDHANI, JIAN LI, ROGER L. NATION Facility for Anti-infective Drug Development & Innovation Drug Delivery,
Mutant Prevention Concentration and the Selection Window Hypothesis Karl Drlica, Xilin Zhao, and Tao Lu Public Health Research Institute Newark, NJ.
PK/PD - ICC - Manila, June 5th, The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place ? Paul.
A Pharmacodynamic Model for Cefprozil against Haemphilus influenzae in an in vitro Infection Model across Multiple Regimens Olanrewaju O. Okusanya, Pharm.D,
PK/PD of Antibiotics in relation to resistance Otto Cars MD Department of Medical Sciences Infectious diseases Uppsala University Sweden.
Pharmacokinetics of Antimicrobials in Animals: Lessons Learned William A. Craig, M.D. University of Wisconsin-Madison.
The Endpoint from a Resistance Point of View A Symposium to Honor the Career of William A. Craig, M.D. George Drusano, M.D. Co-Director Ordway Research.
Issues in testing regimens containing multiple novel agents I. Preclinical Testing Jacques Grosset Johns Hopkins University School of Medicine, Baltimore,
Pharmacodynamics of Antifungals
Pharmacodynamics of Antimicrobials in Animal Models William A. Craig, M.D. University of Wisconsin-Madison.
1 Developments in pK/pD: optimising efficacy & prevention of resistance A critical review of pK/pD in in vitro models Alasdair MacGowan Bristol Centre.
Christine Hesje, BSc; Joseph M. Blondeau, PhD
1 Motivation and philosophy for development of mechanistic PK/PD models in infectious diseases William A. Craig Symposium October 29 th 2008 University.
Antibiotic Resistance Emerging antibiotic resistance is a major health concern. 2 million people in the U.S. infected with antibiotic resistant bacteria.
Pharmacodynamic Indices Canisius-Wilhelmina Hospital Nijmegen, The Netherlands Johan W Mouton.
Pk/Pd modelling : Clinical Implications
Pharmacodynamics of Fluoroquinolones G.L. Drusano, M.D. Professor and Director Division of Clinical Pharmacology Clinical Research Institute Albany Medical.
PK/PD: TOWARDS DEFINITIVE CRITERIA PK/PD in clinical Practice: new level of PK/PD Francesco Scaglione Department of Pharmacology, Toxicology and Chemotherapy,
JWM Grindelwald Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands Johan W. Mouton Pharmacodynamic Indices.
Antibiotics (anti-microbials)
Antibiotic combinations vs. monotherapy in critical care
Setting-up a model of intracellular infection by Pseudomonas aeruginosa for the pharmacodynamic evaluation of antibiotic activity. J. Buyck1, O. Jolois2,
International Society for Anti-infective Pharmacology (ISAP)
Comparison of the intracellular and extracellular activities of approved and novel antistaphylococcal antibiotics using a pharmacodynamic model exploring.
The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place ? Paul M. Tulkens Cellular and Molecular.
Incubation (with antibiotic)
Difference log CFU from time 0
Bad bugs, no drugs and no ESKAPE RESULTS: In vitro experimental data
Introduction: Results: Methodology: Discussion: Conclusion:
Pharmacodynamics of amoxicillin/clavulanic acid against Haemophilus influenzae in an in vitro kinetic model: a comparison of different dosage regimens.
In-vitro interaction of azithromycin and fluoroquinolones against gram-positive and gram-negative bacteria  Matthew W. Ruble, Deborah H. Gilbert, Stephen.
Antibiotic Susceptibility Testing
Antibiotics in 2005: Which one do we need to use and when ?
P1257 Pharmacodynamics of Amikacin Inhale studied in an in vitro pharmacokinetic model of infection KE Bowker, AR Noel, SG Tomaselli, MLG Attwood, AP.
Françoise Van Bambeke, Dr Sc. Pharm, Agr. Ens. Sup.
Antibiotic Resistance Emerging antibiotic resistance is a major health concern. 2 million people in the U.S. infected with antibiotic resistant bacteria.
In vitro activity of several antimicrobial peptides against colistin-susceptible and colistin- resistant Acinetobacter baumannii  X. Vila-Farres, C. Garcia.
Pharmacokinetics and pharmacodynamics of fluoroquinolones
Trends in quinolone susceptibility of Enterobacteriaceae among inpatients of a large university hospital: 1992–98  J. Robert, E. Cambau, K. Grenet, D.
Cell-wall-inhibiting antibiotic combinations with activity against multidrug-resistant Klebsiella pneumoniae and Escherichia coli  R.A. Hickman, D. Hughes,
P. Moreillon, J.M. Entenza  Clinical Microbiology and Infection 
Inga Odenholt, Elisabeth Löwdin, Otto Cars 
The antibacterial effects of ciprofloxacin and trovafloxacin against Streptococcus pneumoniae in an in vitro dynamic model  Matthew O'Brien, Thuy Quach,
Hollow Fiber Infection Model for Antibiotic PK/PD
Comparative in vitro pharmacodynamics of BO-2727, meropenem and imipenem against Gram-positive and Gram-negative bacteria  Inga Odenholt, Elisabeth Löwdin,
M.R. Jacobs  Clinical Microbiology and Infection 
Pharmacodynamics of amoxicillin/clavulanic acid against Haemophilus influenzae in an in vitro kinetic model: a comparison of different dosage regimens.
Can pharmacokinetic–pharmacodynamic parameters provide dosing regimens that are less vulnerable to resistance?  P. Courvalin  Clinical Microbiology and.
The in vitro activity of moxifloxacin against Haemophilus influenzae and Moraxella catarrhalis explored using a pharmacodynamic model  Alasdair P. MacGowan,
Presentation transcript:

Use of in vitro models to study the emergence of resistance Professor Inga Odenholt Department of Infectious Diseases University hospital, Malmö Sweden

The university hospital in Malmö

How to study the emergence of resistance? In vitro with static concentrations (MPC concept) In in vitro kinetic models with fluctuating concentrations In in vitro foreign body kinetic model In animal models In human clinical trials

Different types of in vitro kinetic models Diffusion models –Two compartment models Dilution models, –without filter-membranes –with filter-membranes

The study of enoxacin to determine the Cmax/MIC ratio for bactericidal activity and emergence of resistance Blaser et al. AAC :31; , 1987

Diffusion model

The concentration of enoxacin given as 500 mg BID or 1000 mg OD

Resistence was studied by population analysis and by inoculating the bacteria on antibiotic containing plates 0.33, 1 and 3 mg/L In conclusion: A Cmax/MIC > 8 was needed to prevent regrowth

The efficacy of enoxacin against P. aeruginosa with a MIC of 1 mg/l

Dose ranging and fractionation of ciprofloxacin against P. aeruginosa Marchbanks et al. AAC:37: , 1993

Hollow fiber cartridge

Marchbanks et al. AAC 1993

Marchbanks et. Al. AAC 1993 Killing of P.aeruginosa at three different dosage regimens of ciprofloxacin

Initial MIC=1 mg/l. Sampled at 24 h

Dilutions models

II. Dilution model with filter-membrane Löwdin et.al AAC, 40: , 1996

C=Co x e -kt K= the rate of elimination Co= the concentration in the vessel at time 0 K=F/V F=V x 0.693/t 1/2

Pharmacodynamics of Penicillin G vs S. pneumoniae with different susceptibility for penicillin Odenholt et al AAC; 47:518,2003

T>MIC PSP 46% PIP 6% PRP 0%

T>MIC PSP 75% PIP 38% PRP 0% T>MIC PSP 100% PIP 100% PRP 48%

The concept of Mutant Selective Window Time post-administration MIC MPC Serum or tissue drug concentration Mutant Selection Window C max

Zinner et al. JAC, 2003:52 Emergence of resistant S. pneumoniae exposed to moxifloxacin inside and outside the MSW

Selection of ciprofloxacin resistance in E. coli Olofsson et al. JAC;57: , 2006.

Methods 2 quinolone susceptible strains (ATCC and Nu 14) and one gyr A mutant (nu 118) The MPC was 16xMIC for the susceptible strains and 4 x MIC for NU 118.

Ciprofloxacin concentration fixed at MPC for different time points. T>MPC for 18 h was needed to prevent growth of resistant bacteria

(64xMIC) A Cmax of 64xMIC was needed to prevent growth of resistant bacteria for both susceptible strains

Selection of resistant mutants from Nu 14 (MIC=0.008 mg/l) as a function of Cmax Selection of resistant mutants from Nu 14 (MIC=0.008 mg/l) as a function of Cmax

Results T>MPC of 18 h was sufficient to prevent selection of resistance A Cmax of 64xMIC was needen to prevent selection for the susceptible organisms (8 x MIC for Nu 118). The parameter best predicitve of emergence of resistance was AUC/MPC

Synergy of colistin with rifampin and trim/sulpha against multi-resistant S. maltophilia Giamarellos et al. Diag Microb Inf Dis 44:259-63, 2002

Regrowth was noted at 24 h when the strain was exposed to colistin alone at 1 and 4 x MIC Even though the strain of S. maltophilia was resistant to rifampin, regrowth was prevented at 24 h.

Yen Tan et al. JAC July, 2007 Minocycline + colistin against imipenem-resistant A. baumannii

Neither minocycline or colistin alone demonstrated bactericidal activity. Regrowth appeared at 6 hs. However, the combination was synergistic and bactericidal